Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/1)
    Active Trials
    0(0%)
    Terminated
    1(50%)

    Phase Distribution

    Phase 4
    1
    50%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    1

    Late Stage

    Phase Distribution1 total trials
    Phase 4Post-market surveillance
    1(100.0%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Terminated(1)
    Other(1)

    Detailed Status

    Terminated1
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 41 (100.0%)

    Trials by Status

    terminated150%
    unknown150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    unknown

    The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

    NCT03535220
    terminatedphase_4

    Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

    NCT00122655

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT03535220

    The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

    Unknown
    NCT00122655Phase 4

    Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

    Terminated

    All 2 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    2